CRC Recruiting Report - Overview



Home


Phase I

Focus

Conditions

Procedures

Endpoints



Study Recruitment Funnel			
	100%		
Contacted	4894		
Responded	2558		
Phone Screened	2080		
Screened	670		
Enrolled	405		
Complete	270		
	 5.5%		

Study Focus	Count
⊞ Birth Control	11
⊞ Birth Control, Condition	2
⊕ Condition	9
⊕ Condition, Menopause	1
± HIV	4
	2
Total	29

All Leads by Status				
Status	Count ▼			
NRTC	2336			
DNQ	948			
No	462			
NLI	279			
Done	270			
SF	265			
UNK	175			
DC	99			
Closed	24			
LTFU	23			
Active	13			
Total	4894			

All Leads by Source			
Souce	Count		
Central	3091		
Established	590		
Online	476		
Unknown	346		
Local	139		
WOM	112		
Provider	99		
Emp/Stud	40		
Transfer	1		
Total	4894		

6/17/2016

Earliest Last Contact Attempt

7/1/2024

Latest Contact Attempt

40%

SF Rate

7.30

Contact : Screen Ratio

1.65

Screen: Enroll Ratio

67%

Completion Rate

CRC Recruiting Report - BC Efficacy



Home


Phase I

Focus


Conditions

Procedures

Endpoints



CRC Nickname	Protocol ID	Product Type	BC Type
CCN012B	CCN012B	Ring	Hormonal
CCN013C	CCN013C	Emergency	Non-hormonal
CCN016	CCN016	IUD	Hormonal
CCN017	CCN017	Gel	Hormonal
E4 Freedom	MIT-Es0001-C302	Pill	Hormonal
Mylan Patch	MR-100A-01-TD-3001	Patch	Hormonal
Nexplanon Extension	MK-8415-060	Implant	Hormonal
VeraCept	CMDOC-0042	IUD	Non-hormonal



7.98
Contact : Screen Ratio
SF Rate

1.32
Screen : Enroll Ratio
Completion Rate

CRC Recruiting Report - BC Non-Efficacy



Home


Phase I

Focus

Conditions

Procedures

Endpoints



CRC Nickname	Protocol ID	Product Type	ВС Туре
Dare Ovaprene I	DR-OVP-001	Ring	Non-hormonal
Edelman Study	Edelman	Emergency	Non-hormonal
p50 film	ZB-06-01	Film	Non-hormonal



6.44 52%
Contact : Screen Ratio SF Rate

2.08 68%
Screen : Enroll Ratio Completion Rate

CRC Recruiting Report - Conditions



Home


Phase I

Focus

Conditions

Procedures

Endpoints



Study Recruitment Funnel			
	100%		
Contacted	1877		
Responded	961		
Phone Screened	773		
Screened	173		
Enrolled	32		
Complete	20		
	Н		
	1.1%		

CRC Nickname	Protocol ID	Product Type	Reproductive Condition(s)
Abbvie 283	M16-283	Tablet	Fibroids, Heavy Menstrual Bleeding
Abbvie 815	M12-815	Tablet	Fibroids, Heavy Menstrual Bleeding
Bayer Endo Study	20584	Tablet	Endometriosis
Dare BV Study	DARE-BV1-001	Gel	Bacterial Vaginosis
Dare SST	SST-6006-013	Cream	FSAD
ERC242	ERC-242	Insert	HSDD
EvoGuard	EVO100-311	Gel	Chlamydia, Gonorrhea
Liberty Study	MVT-601-3001	Tablet	Fibroids, Heavy Menstrual Bleeding
Meds360 IUD for HMB	M360-L105	IUS	Heavy Menstrual Bleeding
Myovant Relugolix	MVT-601-050	Pill	Endometriosis, Fibroids
Obseva-Chiltern Study	16-OBE2109	Tablet	Fibroids
Spirit Endometriosis	MVT-601-3101	Tablet	Endometriosis

10.85 Contact : Screen Ratio	82% SF Rate	
5.41 Screen: Enroll Ratio	63% Completion Rate	

CRC Recruiting Report - CONRAD



Home


Phase I

Focus


Conditions

Procedures

Endpoints



CRC Nickname	Protocol ID	Product Type	Focus
Conrad 143	D17-143		Sample Collection
Conrad 146	A18-146	Insert	HIV
Conrad 150	A20-150		HIV
MATRIX	MATRIX-001	Insert	HIV



2.80
Contact : Screen Ratio
SF Rate

1.08
Screen : Enroll Ratio
Completion Rate

CRC Recruiting Report - Misc. Studies



Endpoints

Home Phase I Focus Conditions Procedures

